Accumulated amortization for amortizable intangible assets Finite-Lived Intangible Assets, Accumulated Amortization Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Statistical Measurement [Domain] Statistical Measurement [Domain] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Deferred Shares Deferred Shares [Member] Represents information pertaining to deferred shares. Vested and deferred (in usd per share) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Deferred In Period, Weighted Average Grant Date Fair Value Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Deferred In Period, Weighted Average Grant Date Fair Value Restricted cash Restricted Cash, Current Award Timing Predetermined Award Timing Predetermined [Flag] Related Party Transaction [Axis] Related Party Transaction [Axis] Share-based compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent Entity File Number Entity File Number Additional Paid-in-Capital Additional Paid-in Capital [Member] IPO IPO [Member] Impairment Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Tabular List, Table Tabular List [Table Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Schedule of ordinary shares reserved for future issuance Schedule Of Ordinary Shares Reserved For Future Issuance [Table Text Block] The tabular disclosure of ordinary shares reserved for future issuance. Accounts payable Increase (Decrease) in Accounts Payable Total direct research and development expenses Direct Research And Development Expense Direct Research And Development Expense License revenue License [Member] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Net loss per share attributable to ordinary shareholders, basic (in usd per share) Earnings Per Share, Basic Adjustment to Compensation: Adjustment to Compensation [Axis] Related Party Transactions Related Party Transactions Disclosure [Text Block] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Total Number of shares reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Share based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Gross deferred tax asset Deferred Tax Assets, Gross Schedule of Significant Segment Expenses Schedule of Segment Reporting Information, by Segment [Table Text Block] Laboratory equipment Laboratory Equipment [Member] This member stands for laboratory equipment. Adjustment to Compensation, Amount Adjustment to Compensation Amount Principles of consolidation Consolidation, Policy [Policy Text Block] Share based compensation Share-Based Payment Arrangement, Noncash Expense Stock options Share-Based Payment Arrangement, Option [Member] VOLT Subsidiaries, VOLT [Member] Subsidiaries, VOLT Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Percentage of ordinary shares present to exercise preemptive rights Percentage Of Shares Necessary To Exercise Preemptive Rights The minimum percentage of shares required to exercise preemptive rights. Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Research and development Research and Development Expense, Policy [Policy Text Block] Cash and cash equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Effective Income Tax Rate Reconciliation, Percent [Abstract] Effective Income Tax Rate Reconciliation, Percent [Abstract] Total stockholders’ equity attributable to Barinthus Biotherapeutics plc shareholders Equity, Attributable to Parent Insider Trading Policies and Procedures [Line Items] Share based compensation expense Share-Based Payment Arrangement, Expense Schedule of property and equipment Schedule of property and equipment, net Property, Plant and Equipment [Table Text Block] Ordinary shares, authorized (in shares) Common Stock, Shares Authorized Becaon Topco, Inc Becaon Topco, Inc [Member] Becaon Topco, Inc Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Issue of ordinary shares, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Total liabilities and stockholders’ equity Liabilities and Equity Foreign currency translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Cumulative contributions from noncontrolling interest owner Subsidiary, Cumulative Contributions, Noncontrolling Owner Subsidiary, Cumulative Contributions, Noncontrolling Owner Number of Stock Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentrations of credit risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Expenses Expenses [Member] Expenses LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Cover [Abstract] Cover [Abstract] Maximum Maximum [Member] Other Deferred Tax Assets, Other General and administrative General and Administrative Expense [Member] Exercisable at the end of the period (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Estimated useful life of intangible assets Finite-Lived Intangible Asset, Useful Life Net loss attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Deferred shares, outstanding (in shares) Deferred Stock, Shares Outstanding Number of shares of deferred stock outstanding. Accounting Policies [Abstract] Accounting Policies [Abstract] Schedule of maturities of minimum lease liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Grant fair value of awards Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Pay vs Performance Disclosure [Line Items] Total lease liability Operating Lease, Liability Share Repurchase Program [Line Items] Share Repurchase Program [Line Items] Retirement Benefits [Abstract] Retirement Benefits [Abstract] American Depositary Shares ADR [Member] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Schedule of changes in the valuation allowance for deferred tax assets Summary of Valuation Allowance [Table Text Block] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Ordinary shares, liquidation preference Ordinary Shares, Liquidation Preference The amount of liquidation preference on ordinary shares to be paid after which the deferred shares have the entitlement to receive out of the assets of the Company. Loss before income tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Entity Shell Company Entity Shell Company Other non-current liabilities Other Liabilities, Noncurrent Proceeds from sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Deferred income Increase (Decrease) in Deferred Revenue Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Goodwill impairment Impairment of goodwill Goodwill, Impairment Loss Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Company Selected Measure Amount Company Selected Measure Amount 2028 Lessee, Operating Lease, Liability, to be Paid, Year Three Comprehensive loss/(gain) attributable to noncontrolling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Accrued bonus Accrued Bonuses, Current Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders Comprehensive Income (Loss), Net of Tax, Attributable to Parent Number of depositary shares per share of common stock (in shares) Number Of Depositary Shares Per Share Of Common Stock Number Of Depositary Shares Per Share Of Common Stock Name Measure Name Schedule of loss before income taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of changes in deferred income Deferred Income [Table Text Block] Enterprise Management Incentive Share Option Scheme Enterprise Management Incentive Share Option Scheme [Member] Information pertaining to the Enterprise Management Incentive Share Option Scheme. United Kingdom Income (Loss) from Continuing Operations before Income Taxes, Domestic Schedule of accrued expenses and other current liabilities Accrued Liabilities And Other Current Liabilities [Table Text Block] Tabular disclosure of the components of accrued liabilities and other current liabilities. Operating lease liability - current Lease liability, current Operating Lease, Liability, Current Schedule of financial instruments carried at fair value and classified within Level 3 Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Deferred tax liability, net Total deferred tax, net Deferred Income Tax Liabilities, Net Document Fiscal Period Focus Document Fiscal Period Focus Award Timing Method Award Timing Method [Text Block] Office furniture and equipment Furniture and Fixtures [Member] Award Type [Axis] Award Type [Axis] Legal Entity [Axis] Legal Entity [Axis] Total assets Assets Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Maximum period to exercise preemptive rights Period Of Preemptive Rights To Be Exercised The period allowed to exercise preemptive rights. Share based compensation Share-Based Payment Arrangement [Policy Text Block] Estimated annual amortization expense for 2026 Finite-Lived Intangible Asset, Expected Amortization, Year One Trading Symbol Trading Symbol 2029 Lessee, Operating Lease, Liability, to be Paid, Year Four Total indirect research and development expenses Indirect Research And Development Expense Indirect Research And Development Expense Geographical [Domain] Geographical [Domain] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Changes in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Entity Address, City or Town Entity Address, City or Town CASH FLOWS FROM OPERATING ACTIVITIES: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Deferred shares, authorized (in shares) Deferred Stock, Shares Authorized The maximum number of deferred shares permitted to be issued by an entity's charter and bylaws. Intangible Assets, Net Intangible Assets Disclosure [Text Block] Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] RSU's Restricted Stock Units (RSUs) [Member] Research and Development of Immunotherapies and Vaccines Research And Development Of Immunotherapies And Vaccines [Member] Research And Development Of Immunotherapies And Vaccines Allowance for credit losses Credit Loss, Financial Instrument [Policy Text Block] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Non-cash lease expenses Non-Cash Lease Expenses The amount of non-cash lease expenses. Oxford University Innovation Oxford University Innovation [Member] Represent information related to Oxford University Innovation. Estimated annual amortization expense for 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Four Accrued Expenses and Other Current Liabilities Accrued Liabilities And Other Current Liabilities [Text Block] The entire disclosure of the components of accrued liabilities and other current liabilities. Entity Emerging Growth Company Entity Emerging Growth Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Lease Costs Lease, Cost [Abstract] Exercise of stock options Shares available for future grants (in shares) Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Business Combination [Domain] Business Combination [Domain] Related parties Related Party [Member] Ordinary shares, outstanding (in shares) Common Stock, Shares, Outstanding Schedule of components of income tax benefit (expense) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Plan Name [Axis] Plan Name [Axis] Property and equipment Property, Plant and Equipment, Policy [Policy Text Block] Document Information [Table] Document Information [Table] PEO PEO [Member] Interest income Investment Income, Interest Intangible assets Deferred Tax Liabilities, Intangible Assets Unrealized foreign exchange loss Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Current income tax benefit/(expense): Current Income Tax Expense (Benefit), Continuing Operations [Abstract] United States UNITED STATES Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Changes in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Depreciation Deferred Tax Liabilities, Property, Plant and Equipment Intangible assets acquired through business combinations Intangible Assets, Finite-Lived, Policy [Policy Text Block] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Accumulated Deficit Retained Earnings [Member] Prepaid expenses and other current assets Total Prepaid Expense and Other Assets, Current Income Tax Jurisdiction [Axis] Income Tax Jurisdiction [Axis] Number of Shares Underlying RSUs Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash, cash equivalents and restricted cash, beginning of the period Cash, cash equivalents and restricted cash, end of the period Cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement [Abstract] Income Statement [Abstract] Tax benefit Total income tax benefit Income Tax Expense (Benefit) Sale of Stock [Domain] Sale of Stock [Domain] Other assets Other Assets Deferred shares, nominal value (in gbp per share) Deferred Stock, Par Or Stated Value Per Share Face amount or stated value per share of deferred stock. Restricted share units, options, share appreciation rights and restricted shares Restricted Share Units, Stock Options, Share Appreciation Rights And Restricted Shares [Member] Information pertaining to aggregate awards under a specific share-based compensation plan. Number of geographic regions where the company operates Number Of Geographic Regions In Which Entity Operates Number Of Geographic Regions In Which Entity Operates Document Information [Line Items] Document Information [Line Items] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Product and Service [Domain] Product and Service [Domain] Research and development services Research And Development Services, Policy [Policy Text Block] Disclosure of accounting policy for research and development services. Property and equipment, at cost Property, Plant and Equipment, Gross Total stockholders’ equity attributable to Barinthus Biotherapeutics plc stockholders Parent [Member] Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Employer contribution Defined Contribution Plan, Employer Discretionary Contribution Amount Ordinary shares Stockholders' Equity, Policy [Policy Text Block] Income taxes Regulatory Income Taxes, Policy [Policy Text Block] Other income/(expense): Other Income and Expenses [Abstract] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] City Area Code City Area Code Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Intangible amortization Deferred Tax Assets, Goodwill and Intangible Assets Additional lease term Lessee Operating Lease, Extended Term Term of lessee's operating lease extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Other adjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Settlement payments related to contingent consideration liability Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Barinthus Biotherapeutics plc Share Award Plan 2021 Barinthus Biotherapeutics plc Share Award Plan 2021 [Member] Barinthus Biotherapeutics plc Share Award Plan 2021 Unvested begining balance (in shares) Unvested ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Merger exchange ratio Merger Agreement, Merger Exchange Ratio Merger Agreement, Merger Exchange Ratio CASH FLOWS FROM INVESTING ACTIVITIES: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] General and administrative General and Administrative Expense Long-lived assets Long-Lived Assets Unrecognized compensation cost related to options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Related Party Transactions [Abstract] Related Party Transactions [Abstract] Effective Income Tax Rate Reconciliation [Table] Effective Income Tax Rate Reconciliation [Table] Estimated Useful Life Property, Plant and Equipment, Useful Life Preferred stock par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Subsequent Event Subsequent Event [Member] Schedule of weighted-average assumptions of fair value stock option issued to employees Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Total lease cost Lease, Cost Effective Income Tax Rate Reconciliation [Line Items] Effective Income Tax Rate Reconciliation [Line Items] Deferred Income [Roll Forward] Deferred Income [Roll Forward] Lease liability Deferred Tax Assets, Leasing Arrangements Amount before allocation of valuation allowances of deferred tax asset attributable to lease liability. Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] PEO Total Compensation Amount PEO Total Compensation Amount Depreciation expense Depreciation Vested but subject to deferred settlement (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Number Equity Components [Axis] Equity Components [Axis] Entity Ex Transition Period Entity Ex Transition Period Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Auditor Name Auditor Name Share-based compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Concentration Risk [Table] Concentration Risk [Table] VOLT VOLT [Member] Represent of VOLT Member Employee Benefit Plans Compensation and Employee Benefit Plans [Text Block] Deferred tax assets: Components of Deferred Tax Assets [Abstract] Vested and settled (in usd per share) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Settled In Period, Weighted Average Grant Date Fair Value Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Settled In Period, Weighted Average Grant Date Fair Value Research and development incentives receivable Increase (Decrease) in Research and Development Incentives Receivable Amount of increase (decrease) in research and development incentives receivable. Other Performance Measure, Amount Other Performance Measure, Amount Weighted- average Exercise Price Per Option Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Entity Address, State or Province Entity Address, State or Province Operating lease right-of-use asset impairment charge Operating Lease, Impairment Loss Income Taxes [Line Items] Income Taxes [Line Items] Income Taxes [Line Items] Fair value measurements Fair Value Measurement, Policy [Policy Text Block] Deferred A shares, £1 nominal value; 63,443 shares authorized, issued and outstanding (December 31, 2024: authorized, issued and outstanding: 63,443) Deferred Stock, Value Issued Aggregate par or stated value of issued deferred stock. Related and Nonrelated Parties [Domain] Related and Nonrelated Parties [Domain] Total current liabilities Liabilities, Current Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Maximum aggregate nominal amount of shares authorized to be allotted free from pre-emption rights Maximum Aggregate Nominal Amount Of Shares Authorized To Be Allotted Free From Statutory Pre-emption Rights Amount of maximum aggregate nominal amount of shares that the board of directors are authorized to allot free from statutory Pre-emption rights. Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Clywedog Therapeutics, Inc. Clywedog Therapeutics, Inc. [Member] Clywedog Therapeutics, Inc. Individual: Individual [Axis] Financial instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Income Tax Jurisdiction [Domain] Income Tax Jurisdiction [Domain] Other Other Assets, Current Document Annual Report Document Annual Report Research and development Research and Development Expense [Member] Cash payments received Deferred Income, Addition Entity [Domain] Entity [Domain] Net cash provided by/(used) in investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Document Fiscal Year Focus Document Fiscal Year Focus Right of use assets, net Right-of-use asset Operating Lease, Right-of-Use Asset Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Accrued payroll and employee benefits Accrued Employee Benefits, Current Noncontrolling interest percentage Subsidiary, Ownership Percentage, Noncontrolling Owner Capitalized Research and Development expenditure Deferred tax assets for capitalized research and development expenditure Deferred Tax Asset, In-Process Research and Development Effective tax rate Effective Income Tax Rate Reconciliation, Percent Entity Interactive Data Current Entity Interactive Data Current Operating leases Operating Lease, Cost Facility related Facility Related [Member] Facility Related Plan Name [Domain] Plan Name [Domain] Transaction-related fees Business Combination, Acquisition-Related Cost, Expense Leasehold improvement expense Leasehold Improvements, Gross Weighted-average period over which unrecognized compensation cost is expected to be recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Valuation allowance Valuation allowance Valuations allowance at beginning of year Valuation allowance at end of year Deferred Tax Assets, Valuation Allowance Equity [Abstract] Equity [Abstract] Percentage of issued and outstanding ordinary shares available for issuance Share-Based Compensation, Percentage Of Shares Available For Issuance As A Percentage Of Issued And Outstanding Shares Total number of shares available for issuance under the Plan as a percentage of the Company's issued and outstanding shares. Exercisable, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Segment information Segment Reporting Disclosure [Text Block] Direct research and development expenses: Direct Research and Development Expenses [Abstract] Direct Research and Development Expenses Foreign exchange translation Deferred Income, Foreign Exchange Translation Gain (Loss) Deferred Income, Foreign Exchange Translation Gain (Loss) Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Other Commitments [Line Items] Other Commitments [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Ownership [Domain] Ownership [Domain] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Amortization expense for intangible assets Amortization of Intangible Assets Leases Lessee, Leases [Policy Text Block] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Depreciation and amortization Depreciation, Depletion and Amortization Customer [Domain] Customer [Domain] Entity Central Index Key Entity Central Index Key PEO Name PEO Name Schedule of Company’s Long-Lived Assets Schedule of Revenues from External Customers and Long-Lived Assets [Table] Accumulated other comprehensive loss – foreign currency translation adjustments Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Number of Reportable Segments Not Disclosed Flag Number Of Reportable Segments Not Disclosed Flag Number Of Reportable Segments Not Disclosed Flag Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] VTP-1000 Celiac VTP-1000 Celiac [Member] VTP-1000 Celiac Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Contingent consideration liability Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Arrangement Duration Trading Arrangement Duration Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Segments [Axis] Segments [Axis] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Exercise Price Award Exercise Price Entity Filer Category Entity Filer Category Local Phone Number Local Phone Number Class of Stock [Domain] Class of Stock [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Vested and deferred (in shares) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Deferred In Period Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Deferred In Period Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Contingent liabilities Contingent Liability Reserve Estimate, Policy [Policy Text Block] Statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Subsequent Event Type [Axis] Subsequent Event Type [Axis] Share-Based Compensation Share-Based Payment Arrangement [Text Block] Stock conversion ratio Stock Conversion Ratio Stock Conversion Ratio Other indirect costs Other Indirect Costs [Member] Other Indirect Costs ASSETS Assets [Abstract] Noncontrolling interest Minority Interest [Policy Text Block] Disclosure of accounting policy for Minority (Non Controlling) interest. Expiration period Expiration Of Share Based Compensation Plan From Date Of Initial Issuance The duration of grants awarded under a share-based compensation plan. Underlying Security Market Price Change Underlying Security Market Price Change, Percent Estimated annual amortization expense for 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Three Forfeited (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Fair Value Fair Value Disclosures [Text Block] Gross amount of amortizable intangible assets Finite-Lived Intangible Assets, Gross Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Research and development Total research and development expenses Research and Development Expense Schedule of right-of-use assets, lease liabilities and other information Lessee Operating Lease Right of Use asset and Other Information [Table Text Block] Tabular disclosure for Company's right-of-use asset and lease liability and other information. Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Operating lease liability - non-current Lease liability, non-current Operating Lease, Liability, Noncurrent Entity Voluntary Filers Entity Voluntary Filers Ownership [Axis] Ownership [Axis] Deferred Shares Stockholders Equity Deferred Shares Disclosure [Text Block] The entire disclosure for Deferred Shares as disclosed by the entity. In-License Agreements In-License Agreements [Member] Represents the information pertaining to In-License Agreements. Foreign exchange translation Valuation Allowance, Deferred Tax Asset, Increase (Decrease) Resulting From Foreign Currency Translation Valuation Allowance, Deferred Tax Asset, Increase (Decrease) Resulting From Foreign Currency Translation Fair Value as of Grant Date Award Grant Date Fair Value Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Entity Registrant Name Entity Registrant Name Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Net operating loss carryforwards Operating Loss Carryforwards Audit Information [Abstract] Audit Information [Abstract] Awards granted (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Related Party Transaction [Line Items] Related Party Transaction [Line Items] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Counterparty Name [Domain] Counterparty Name [Domain] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Two Number of operating segments Number of Operating Segments Patent and licensing costs Intangible Assets, Costs Incurred to Renew or Extend, Policy [Policy Text Block] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Outstanding, Weighted-average remaining contractual term (Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Related and Nonrelated Parties [Axis] Related and Nonrelated Parties [Axis] Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Restatement Determination Date: Restatement Determination Date [Axis] Impairment charge Impairment of Long-Lived Assets to be Disposed of Non-PEO NEO Non-PEO NEO [Member] Foreign Deferred Foreign Income Tax Expense (Benefit) Outstanding, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Schedule of prepaid and other current assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Right-of-use lease asset Deferred Tax Liabilities, Leasing Arrangements Vested and settled (in shares) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Settled In Period Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Settled In Period Sale of Stock [Axis] Sale of Stock [Axis] Effect of change in tax laws or rates enacted in the current period Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Name Trading Arrangement, Individual Name Award Type [Domain] Award Type [Domain] Beginning balance Ending balance Deferred Income 2026 Lessee, Operating Lease, Liability, to be Paid, Year One Noncontrolling interest Equity, Attributable to Noncontrolling Interest Equity Awards Adjustments Equity Awards Adjustments [Member] Leasehold improvements Leasehold Improvements [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Grant Income Other Operating Income and Expense [Text Block] Compensation Amount Outstanding Recovery Compensation Amount Deferred income tax benefit: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Switzerland SWITZERLAND Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Outstanding (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Grant Date Fair Value MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Name Awards Close in Time to MNPI Disclosures, Individual Name Unvested beginning balance (in usd per share) Unvested ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Change in contingent consideration Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Cash equivalents Cash Equivalents, at Carrying Value Accrued manufacturing and clinical expenses Accrued Manufacturing and Clinical Expenses, Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing and clinical expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Share based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Research and Development Type [Axis] Research and Development Type [Axis] Research and Development Type Deferred shares, issued (in shares) Deferred Stock, Shares Issued Total number of deferred shares of an entity that have been sold or granted to shareholders Oxfordshire Oxfordshire [Member] Oxfordshire Tax credits Effective Income Tax Rate Reconciliation, Tax Credits, Research And Development, Amount Effective Income Tax Rate Reconciliation, Tax Credits, Research And Development, Amount Net deferred tax liabilities Deferred Tax Liabilities, Gross Foreign Tax Effects Foreign Tax Jurisdiction [Member] Auditor Firm ID Auditor Firm ID Increases recorded to income tax provision Valuation Allowance, Deferred Tax Asset, Increase Resulting From Income Tax Provision Valuation Allowance, Deferred Tax Asset, Increase Resulting From Income Tax Provision Segments [Domain] Segments [Domain] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Research and development incentives Research And Development Incentive Income (Expense) Represents the research and development incentives (expenses) for the period. Value Added Tax receivable Value Added Tax Receivable, Current Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Foreign exchange translation recognized in other comprehensive loss Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) Non-cash interest expense Non-Cash Interest Expense On Convertible Loan Notes Amount of non-cash interest expense on convertible loan notes. Scheme Shares Scheme Shares [Member] Scheme Shares Developed technology Developed Technology Rights [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Minimum Minimum [Member] Refundable security deposit Security Deposit Value Added Tax payable Sales and Excise Tax Payable, Current Less: accumulated depreciation and impairment charges Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Net loss per share Earnings Per Share, Policy [Policy Text Block] Company Selected Measure Name Company Selected Measure Name Revenue Revenue [Policy Text Block] Percentage of future royalties for direct sales of a covered product Percentage of Future Royalties for Direct Sales of Covered Product , License Agreement Percentage of future royalties for direct sales of a covered product under the In-License Agreements. Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Number of votes per common share (in votes) Common Stock Number of Votes Per Share The number of votes that each common share is entitled. Accounts payable Accounts Payable, Current Operating cash flows from operating leases Operating Lease, Payments Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] All Executive Categories All Executive Categories [Member] Schedule of significant components of deferred tax assets and liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Other operating income Other Operating Income Ordinary shares, £0.000025 nominal value; 40,848,893 shares authorized, issued and outstanding (December 31, 2024: authorized, issued and outstanding: 40,234,663) Common Stock, Value, Issued Foreign Current Foreign Tax Expense (Benefit) Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Weighted-average ordinary shares outstanding, diluted (in shares) Weighted-average ordinary shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Commitments and contingencies (Note 16) Commitments and Contingencies Vested but subject to deferred settlement (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Grant Date Fair Value Prepaid and Other Current Assets Prepaid Expense and Other Assets, Current [Text Block] The entire disclosure on prepaid expense and other current assets. Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Cumulative contributions from controlling interest owner Subsidiary, Cumulative Contributions, Parent Subsidiary, Cumulative Contributions, Parent Business Combination [Axis] Business Combination [Axis] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Entity Small Business Entity Small Business Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Noncontrolling Interest Noncontrolling Interest [Member] Undistributed earnings of subsidiaries Deferred Tax Liabilities, Undistributed Foreign Earnings Document Transition Report Document Transition Report Research and development incentives Research And Development, Incentives [Policy Text Block] Disclosure of accounting policy for Incentives received o to be received from Research and Development. Schedule of concentration of credit risk Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Noncontrolling Interest [Table] Noncontrolling Interest [Table] Underlying Securities Award Underlying Securities Amount Concentration Risk [Line Items] Concentration Risk [Line Items] Equity Component [Domain] Equity Component [Domain] Document Period End Date Document Period End Date Schedule of Long-Lived Assets Long-Lived Assets by Geographic Areas [Table Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Forfeited/expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Income Taxes Income Tax Disclosure [Text Block] Accounts receivable allowance for credit losses Accounts Receivable, Allowance for Credit Loss U.K. United Kingdom UNITED KINGDOM Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Scenario [Axis] Scenario [Axis] Exercisable, Weighted-average remaining contractual term (Years) (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Operating lease liabilities Increase (Decrease) in Operating Lease Liability Total stockholders’ equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Accruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Document Type Document Type Outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Net Loss Per Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Additional paid-in capital Additional Paid in Capital Product and Service [Axis] Product and Service [Axis] Proceeds from issue of ordinary shares, net of issuance costs Proceeds from Issuance of Common Stock Revenue Revenue from Contract with Customer Benchmark [Member] Total revenue Revenue recognized Revenue from Contract with Customer, Excluding Assessed Tax All Individuals All Individuals [Member] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Name Forgone Recovery, Individual Name Expiration term Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Tax credits Effective Income Tax Rate Reconciliation, Tax Credits, Research And Development Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development tax credit. Impairment of long-lived assets Asset Impairment Charges (Excluding Goodwill) Asset Impairment Charges (Excluding Goodwill) Forfeited/expired (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Self-tender offer authorized amount to purchase Share Repurchase Program, Authorized, Amount Issue of shares from the exercise of stock options Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Aggregate intrinsic value of stock options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Other Operating Income Other Operating Income, Policy [Policy Text Block] Other Operating Income, Policy Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Table] Current liabilities: Liabilities, Current [Abstract] Research and development credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards, Research Additional Disclosures Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Geographical [Axis] Geographical [Axis] Avidea Avidea [Member] This member stands for Avidea. Total operating expenses Operating Expenses Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Research and development incentives receivable Research and Development Incentives Receivable Amount of research and development incentives receivable. Net foreign exchange (loss) gain Gain (Loss), Foreign Currency Transaction, before Tax Related Party Transaction [Table] Related Party Transaction [Table] Net loss per share attributable to ordinary shareholders, diluted (in usd per share) Earnings Per Share, Diluted Forecast Forecast [Member] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Title of 12(b) Security Title of 12(b) Security Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Earnings Per Share [Abstract] Earnings Per Share [Abstract] 2030 Lessee, Operating Lease, Liability, to be Paid, Year Five Net payments received for allowable sublicenses of technology developed Percentage Of Net Payments Received For Allowable Sublicenses Of Technology Developed License Agreement Percentage of net payments received for allowable sublicenses of technology developed under the In-License Agreements. Total other income, net Nonoperating Income (Expense) Controlling interest percentage Subsidiary, Ownership Percentage, Parent Valuation Allowance [Roll Forward] Valuation Allowance [Roll Forward] Valuation Allowance Auditor Location Auditor Location Oxford University Innovation Limited (OUI) Oxford University Innovation Limited [Member] Represents the information pertaining to Oxford University Innovation Limited. Research and development tax credit carryforwards Tax Credit Carryforward, Amount Comprehensive loss Comprehensive Income, Policy [Policy Text Block] Domestic Tax Jurisdiction Domestic Tax Jurisdiction [Member] Number of new subsidiaries Number Of New Subsidiaries Number Of New Subsidiaries Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Exercised (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Estimated annual amortization expense for 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Two Award Timing Disclosures [Line Items] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Property and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Total minimum lease payments Lessee, Operating Lease, Liability, to be Paid Ordinary Shares Equity [Text Block] Clinical trial costs Clinical Trial Costs [Policy Text Block] Disclosure of accounting policy for Clinical Trial costs. Net loss attributable to Barinthus Biotherapeutics plc shareholders Net Income (Loss) Attributable to Parent Subsequent Event [Table] Subsequent Event [Table] Merger agreement extension period Merger Agreement, Extension Period Merger Agreement, Extension Period Expiration Date Trading Arrangement Expiration Date Non-current liabilities: Liabilities, Noncurrent [Abstract] Accrued other Other Accrued Liabilities, Current Estimated annual amortization expense for 2030 Finite-Lived Intangible Asset, Expected Amortization, Year Five Amounts of related party transactions Related Party Transaction, Amounts of Transaction Schedule of Reconciliation to the effective tax rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Stockholders’ equity: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Standard payment terms Accounts Receivable, Standard Payment Terms, Period Accounts Receivable, Standard Payment Terms, Period Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Other adjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Adoption Date Trading Arrangement Adoption Date Maximum additional contingent consideration payments upon achievement of milestones Business Combination, Contingent Consideration, Range of Outcomes, Maximum, Amount Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Deferred income Deferred Income, Current Entity Current Reporting Status Entity Current Reporting Status Maximum funding amount Funding Amount, Maximum Funding Amount, Maximum Customer [Axis] Customer [Axis] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Coalition For Epidemic Preparedness Innovations Coalition For Epidemic Preparedness Innovations [Member] Coalition For Epidemic Preparedness Innovations Loss from operations Operating Income (Loss) Consolidated Entities [Domain] Consolidated Entities [Domain] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Statutory tax rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Schedule of share based compensation expense Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Profit on sale of property and equipment Gain on sale of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Executive Category: Executive Category [Axis] Shares available for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Current Fiscal Year End Date Current Fiscal Year End Date Class of Stock [Axis] Class of Stock [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Impairment of intangible assets Impairment of Intangible Assets, Finite-Lived Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Payables and Accruals [Abstract] Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Shares available for future stock incentive plan awards Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Other income Other Nonoperating Income (Expense) Statement [Table] Statement [Table] Additional paid-in capital Additional Paid In Capital [Policy Text Block] Disclosure of accounting policy for Additional paid in capital. Effect of exchange rates on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Deferred tax benefit Deferred Income Tax Expense (Benefit) Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Non-taxable or non-deductible items Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent Weighted-average grant date fair value (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Other foreign Foreign Tax Jurisdiction, Other [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Issued Estimated annual amortization expense for 2031 Finite-Lived Intangible Asset, Expected Amortization, Year Six Finite-Lived Intangible Asset, Expected Amortization, Year Six Effect of change in tax laws or rates enacted in the current period Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Nature of Business and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Other information Other Information, Lessee [Abstract] Other Information, Lessee Maryland MARYLAND Shares issuable for stock options that were excluded from the computation of diluted weighted-average shares outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] All Adjustments to Compensation All Adjustments to Compensation [Member] Amendment Flag Amendment Flag Other Commitments [Table] Other Commitments [Table] Personnel-related (including share-based compensation) Personnel Related [Member] Personnel Related Termination Date Trading Arrangement Termination Date Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Measure: Measure [Axis] Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Schedule of stock option activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Changes in valuation allowance arising from in-year additions Valuation Allowance, Deferred Tax Asset, Increase Resulting From Current Period Additions Valuation Allowance, Deferred Tax Asset, Increase Resulting From Current Period Additions Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Weighted-average ordinary shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Schedule of computation of basic and diluted net (loss)/income per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Share Repurchase Program [Table] Share Repurchase Program [Table] Related Party Transaction [Domain] Related Party Transaction [Domain] Exercisable at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Size of space under lease agreement (in square feet) Number Of Square Feet Under Lease Agreement Represents the information pertaining to number of Square Feet Under Lease Agreement. Subsequent Events [Abstract] Subsequent Events [Abstract] Segment Reporting [Abstract] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Income Taxes [Table] Income Taxes [Table] Income Taxes [Table] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Entity Tax Identification Number Entity Tax Identification Number Scenario [Domain] Scenario [Domain] Other operating income recognized related to the Funding Agreement Other operating income recognized related to the Funding Agreement Deferred Income, Revenue Recognized Outstanding at the beginning of the period (in usd per share) Outstanding at the end of the period (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Consolidated Entities [Axis] Consolidated Entities [Axis] Ordinary shares, nominal value (in gbp per share) Ordinary shares, nominal value (per share) Common Stock, Par or Stated Value Per Share Ordinary shares, issued (in shares) Common Stock, Shares, Issued Weighted average remaining lease term (years) Operating Lease, Weighted Average Remaining Lease Term Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Barinthus legacy assets Barinthus Legacy Assets [Member] Barinthus Legacy Assets Use of estimates Use of Estimates, Policy [Policy Text Block] Entity Public Float Entity Public Float Scheme exchange ratio Merger Agreement, Scheme Exchange Ratio Merger Agreement, Scheme Exchange Ratio Interest expense Interest Expense, Nonoperating Trading Arrangement: Trading Arrangement [Axis] Total Shareholder Return Amount Total Shareholder Return Amount Concentration risk, percentage Concentration Risk Threshold Percentage For an entity that discloses a concentration risk threshold Percentage in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. Change in fair value recognized in net loss Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Guarantees and indemnifications Guarantees, Indemnifications and Warranties Policies [Policy Text Block] Subsequent Events Subsequent Events [Text Block] Other comprehensive gain/(loss) – foreign currency translation adjustments Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Insider Trading Arrangements [Line Items] Security Exchange Name Security Exchange Name Total liabilities Liabilities Non-taxable or non-deductible items Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount Clywedog Capital Stock Clywedog Capital Stock [Member] Clywedog Capital Stock Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Prepayments Prepaid Expense, Current Operating expenses Operating Expenses [Abstract] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Foreign Currency Translation in General and Administrative Expenses Foreign Currency Disclosure [Text Block] Accrued expenses and other current liabilities Total Accrued Liabilities and Other Liabilities, Current Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Foreign Currency [Abstract] Foreign Currency [Abstract] Issue of ordinary shares, net of issuance costs Stock Issued During Period, Value, New Issues Statement [Line Items] Statement [Line Items] Research and Development Type [Domain] Research and Development Type [Domain] Research and Development Type [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalent Counterparty Name [Axis] Counterparty Name [Axis] Schedule of Restricted Stock Units activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Subsequent Event [Line Items] Subsequent Event [Line Items] Deferred tax liabilities: Components of Deferred Tax Liabilities [Abstract] Additional number of shares available for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Ordinary shares Ordinary Shares Common Stock [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-NEOs Non-NEOs [Member] Indirect research and development expenses: Indirect Research and Development Expenses [Abstract] Indirect Research and Development Expenses Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Accrued professional fees Accrued Professional Fees, Current